Rhabdomyosarcoma (RMS) has deregulated proliferation and is blocked in the differentiation program despite Myf-5, MyoD and myogenin expression. Here we show that ectopic expression of MRF4, which is not subject to an autoregulatory pathway but regulated by the other MRFs protein family, induces growth arrest and terminal differentiation in RD cells. Deletion mapping identified a positive-acting C-terminal domain in MRF4 as the mediator of transcriptional activity, revealing a conserved motif with helix III in MyoD previously found to initiate expression of endogenous skeletal muscle genes. By using chimeric MyoD/MRF4 proteins, we observe that the Cterminal motif of MRF4 rescues MyoD activity in RD cells. Moreover, comparative induction of muscle-specific genes following activation of MyoD, through the expression of a constitutively activated MKK6 either in the absence or presence of MRF4, shows that MyoD and MRF4 can differently regulate muscle genes expression.
Introduction
Rhabdomyosarcomas (RMSs), one of the most common solid tumors of childhood, arise from muscle precursor cells and fail to complete the differentiation program despite the expression of muscle regulatory factors such as MyoD and myogenin (Diaz et al., 1992; Tapscott et al., 1993) . RMS is characterized by deficiencies in differentiation progress and ability to exit the cell cycle because of MyoD inactivation in these cells. Rescue by heterokaryon fusion with fibroblasts suggested that a positive regulatory pathway toward MyoD might be deficient in RMS (Tapscott et al., 1993) . Induction of terminal differentiation by induction of p38 MAPK with an activated MAPK kinase 6 (MKK6EE) in RD cells has been recently shown . However, p38 MAPK stimulates MyoD activity by a mechanism that does not involve the interaction with either p38 MAPK substrate or the direct phosphorylation of MyoD. Thus, p38 MAPK could indirectly activate MyoD by targeting b-HLH-interacting proteins or cofactors .
RMS cell lines such as RD, Rh28 or Rh30 express MyoD and myogenin (Tapscott et al., 1993) . These proteins, although they can apparently bind DNA, are transcriptionally inactive. Ectopic expression of MyoD or myogenin cannot induce reversion of the tumoral phenotype even in the presence of exogenous cyclindependent kinase inhibitors (CKIs) or myogenic cofactors (Otten et al., 1997; Knudsen et al., 1998) . The MRF4 gene, member of the MyoD family (Myf-5; MyoD myogenin and MRF4; Edmondson and Olson, 1993; Olson and Klein, 1994) , is not subject to an autoregulatory pathway and MRF4 expression is regulated by the three other MRFs through a crossregulatory circuit. Members of the MEF2 family of transcription factors are also able to transactivate the MRF4 promoter; however, this activation is weak and appears to function via an indirect mechanism (Black et al., 1995) . Since MRF4 expression is under the control of the other MRFs, which are nonfunctional as transcriptional activators in RMS cell lines, MRF4 expression is undetectable in these cells. Surprisingly, forced expression of MRF4 has never been tested in RMS cells, although this gene has a particular expression pattern during myogenesis (Bober et al., 1991; Hinterberger et al., 1991) . Ectopic expression of MRF4 in the RD cell line was undertaken in order to define the relation between MRF4 functions and differentiation of tumor cells.
We report here that ectopic expression of MRF4 induces exit from the cell cycle and myogenic differentiation in RD cells, a process that is enhanced when CKIs are present. We demonstrate that the activity of MRF4 is encoded in large part by the C-terminal region containing a conserved amphipathic a-helix (helix III). Helix III appears to have evolved distinct functions in MyoD and myogenin, functioning as a specification domain in MyoD, that is, a domain critical for the efficient initiation of skeletal muscle gene expression, and as a general transcription activation domain in myogenin (Bergstrom and Tapscott, 2001) . Our data indicate that the C-terminal domain in MRF4 has these two functions in RD cells. In the course of RD cell differentiation, MyoD and MRF4 can act in synergy in muscle-specific expression but they show target gene specificity. Altogether, these data suggest that specific mechanisms may exist for repression/activation of MRF activity in RMS cells.
Results

Muscle differentiation in RD cells is induced by ectopic expression of MRF4
RMS cell lines such as RD, RH18 and RH30 express high levels of MyoD and myogenin proteins, but do not differentiate into muscle skeletal cells because MyoD and myogenin are non functional as a transcriptional activator (Tapscott et al., 1993) . Western blot analysis demonstrated that the RD cell line used in this study contained normal amounts of MyoD, and myogenin compared with the amounts detected in mouse C2C12 cells but very low or undetectable amounts of Myf-5 and MRF4 ( Figure 1a ). To determine if the non functionality as myogenic transcription factors of MyoD and myogenin in RD cells was due to mutations, we first performed transient transfection assays in 10T1/2 cells with ectopic MyoD, myogenin or MRF4 expression vectors and the muscle reporter construct MCK-Luc. MyoD, myogenin and MRF4 expression vectors induced high levels of luciferase activity in 10T1/2 cells cultured in DM (Figure 1b) . In RD cells cultured in DM, overexpression of MyoD and/or myogenin failed to transactivate the muscle reporter construct MCKLuc, contrasting with ectopic expression of MRF4 that induced luciferase activity 25-fold greater than the empty vector (Figure 1b) . These data confirm the recessive defect in MyoD and myogenin in muscletransactivation activity although ectopic expression of MyoD, myogenin and/or MRF4 may induce G1 arrest in RD cells (Figure 1c ).
P21 and p57
kip2 increase MRF4 but not MyoD-or myogenin-mediated muscle-specific gene expression in RD cells Cyclin-Cdk complexes can block the ability of either MyoD or myogenin to activate the expression of muscle Cells were cultured in DM and harvested 48 h later. Aliquots (10 mg) of whole-cell extracts were separated by 10% SDS-PAGE and HAtagged proteins were detected by immunoblotting with anti-HA antibodies (12C5A). Luciferase activities were determined with equivalent quantities of proteins (15 mg) in triplicate and repeated at least twice. (c) RD cells were transiently cotransfected with expression plasmids encoding MyoD, myogenin or MRF4 (1.5 mg) together with GPP (0.1 mg), and 48 h later GFP-expressing cells were analysed for DNA content by flow cytometry " MRF4 C-terminus induces muscle differentiation in RD cells V Sirri et al reporter constructs (Rao et al., 1994; Skapek et al., 1995; Zhang et al., 1999) . The activity of MRFs can be restored significantly by cotransfection with CKIs (Skapek et al., 1995 , Reynaud et al., 1999 . MyoD, myogenin and MRF4 expression vectors induced highest levels of luciferase activity when cotransfected with expression vectors encoding CKIs (Figure 2a ). In contrast in RD cells, overexpression of MyoD and/or myogenin cotransfected with p21 or p57
Kip2 failed to induce MCK-Luc activity (Figure 2b ). On the other hand, in a dose-dependent manner, MRF4 induced Luciferase activity, which was increased in the presence of p21 and p57
Kip2 ( Figure 2b ). These data show the inability of MyoD and myogenin to function in RD cells even in the presence of CKIs whereas they potentialize MRF4-mediated transactivation of muscle-specific genes in proliferating cells maintained in high concentrations of serum. This suggests that differences between myogenic factors transactivation are not dependent on cyclin-Cdk activities.
MRF4 contains a C-terminal activation domain
To understand how MRF4 activated MCK-Luc-dependent transactivation, we tested different regions of MRF4 for intrinsic activation. Various deletion mutants were fused to the HA-tagged Gal4 DBD and expressed in 10T1/2 fibroblasts and/or RD cells with a Gal4-responsive reporter (Figure 3a ). Gal4-MRF4wt gave only a modest stimulation (threefold) compared with Gal4 DBD alone in normal and tumoral cells (Figure 3b ), whereas GAL4-MRF4 1-60, which contains the transactivation domain (TAD) previously described (Mak et al., 1992) , increased transcription 40-fold in 10T1/2 Cip1 or p57 Kip2 (0.5 and 2 mg, respectively). Expression vector without insert was included to normalize DNA in all transfections. Luciferase activities were determined 48 h after transfection in GM. Protein concentration was equalized by the Bradford method. Typically, 15 mg proteins of total cell extracts were used for each reaction carried out in triplicate and repeated at least twice MRF4 C-terminus induces muscle differentiation in RD cells V Sirri et al cells and 20-fold in RD cells compared with Gal4 DBD alone. Surprisingly, activation by GAL4-MRF4 183-242 in RD cells was fourfold higher than the wellcharacterized TAD located in the NH 2 terminal portion of MRF4 (Figure 3b ). To further characterize this new transactivation domain, Gal4-MRF4wt, Gal4-MRF4 1-60 and Gal4-MRF4 183-242 were expressed in normal and transformed nonmuscle and muscle cells. Gal4-MRF4 183-242 showed very important activation domain activity in all muscle cells tested, driving expression of the reporter approximately 5-20-fold higher than in nonmuscle cells. On the other hand, Gal4-MRF4 1-60 promoted transcription to a level roughly 1.5-2-fold higher in nonmuscle cells than in muscle cells except in L6 muscle cells in which the transcriptional activation of the reporter was modest (Figure 3c ). Altogether, these results show that MRF4 contains a C-terminus activation domain, which could be implicated in its myogenic functions in RD cells.
C-terminal motif of MRF4 rescues MyoD activity in RD cells
The sequence alignment of residues 183-242 from the Cterminal region of MRF4 from diverse species shows that an internal domain covering aa 213-233 is highly conserved in MRF4 proteins ( Figure 4a ). Secondary structure predictions indicate that this conserved motif contains an amphipathic a-helical structure. Sequence alignment between the C-terminal domain of MRF4 and the C-terminal domain of MyoD (aa 220-318) showed that the amphipathic a-helix in MRF4 is present in MyoD at residue position 245-258. This MyoD domain encodes an important function that distinguishes MyoD as a specification factor (Bergstrom et al., 2001 ). This motif, named helix III by others (Rhodes and Konieczny, 1989; Fujisawa-Sehara et al., 1990; Meedel et al., 1997) , can adopt an amphipathic a-helical structure highly conserved in MyoD from diverse species (Bergstrom et al., 2001) . This prompted us to determine whether structural features of this domain could account for its functional characteristic in RD cells. We replaced the murine MyoD C-terminal domain with the comparable region from murine MRF4 and conversely the murine MRF4 C-terminal domain with the comparable region of MyoD (Figure 4b ). Expression vectors encoding the chimeric proteins were transfected in 10T1/2 and RD cells. After transfection, cells were cultured in DM and then examined for muscle differentiation by measuring the expression of musclespecific marker Troponin T (TnT). Overexpression of MyoD and/or MyoD/MRF4 chimera in 10T1/2 cells led to a comparable elevated expression of TnT, whereas MRF4 and MRF4/MyoD chimera did not induce significantly expression of TnT (Figure 4c ). In contrast, in transfected RD cells, expression of MRF4 and to a lesser extent MyoD/MRF4 chimera induced high levels of TnT, while MRF4/MyoD chimera and MyoD expression were ineffective. These results demonstrate that in RD cells, the C-terminal domain of MRF4 is essential for this activity. A chimera that introduced the MRF4 C-terminus in MyoD has increased activation function compared to the wild-type MyoD, indicating that the MRF4 C-terminus MRF4 domain is sufficient in the context of MyoD to function as specification 
MRF4 C-terminus induces muscle differentiation in RD cells V Sirri et al
Sequential induction of MyoD and/or MRF4 in RD cells shows functional distinction in the transactivation of muscle-specific genes
It has been shown that introduction of a constitutive activated form of MKK6 (MKK6EE) overrides repression of MyoD and reactivates myogenic differentiation in RMS cells . On the other hand, to further investigate the impact of MRF4 effects on the differentiation process in RD cells, we established a stable RD cell line that constitutively expresses the Tet repressor and inducibly expresses MRF4 (RD-TRM11 clone). The addition of tetracycline to the culture medium induced a high accumulation of MRF4 protein in the nucleus (Figure 5a ). RD-TRM11 cells were transiently cotransfected with expression vectors encoding myc-tagged MKK6wt, MKK6DD (constitutively activated) and/or MKK6AA (inactive) together with MCK-luc reporter. After transfection, cells were cultured in DM for 4 days in the absence or presence of tetracycline to induce MRF4 expression and then examined for luciferase activity. As previously observed, the basal activity of MyoD is virtually undetectable in RD cells (Tapscott et al., 1993 (Olson, 1990 ). An MRF4 functional transcriptional activation domain located within amino acids 10-30 has been previously shown to be both necessary and sufficient to elicit a transcriptional response in 10T1/2 and NIH3T3 fibroblasts (Mak et al., 1992) . We have identified a functional transactivation domain located within amino acids 183-242 exclusively active in normal or tumoral muscle cells (Figure 3) . The 59-amino-acid sequence, overall conserved among MRF4 species, contains a short domain covering amino acids 213-230, which encodes an amphipathic a-helix present in MyoD at residue position 245-258 (helix III) (Figure 4a ). The MyoD helix III has been shown to facilitate the initiation of endogenous gene expression (specification). In contrast to the myogenin helix III, the MRF4 helix III was capable of functionally substituting for MyoD with the same efficiency by conferring a specific activity necessary to initiate expression of endogenous muscle genes in 10T1/2 cells (Bergstrom et al., 2001) . These data and our present work demonstrate that the helix III in MRF4 shares the same efficient initiation of the expression of at least a subset of endogenous skeletal muscle genes. Moreover, in RD cells the C-terminal motif of MRF4 rescues MyoD activity whereas the C-terminal motif of MyoD did not, suggesting that helix III might be further facilitated or regulated by interactions that are dependent on this region. The mechanism by which the MRF4 helix III increases the efficiency of endogenous gene initiation remains unknown. This region might be necessary for the activation of a subset of skeletal muscle promoters, by overcoming promoter-specific negative regulators. In contrast to the C-terminus MyoD, which is not an activation domain (Weintraub et al., 1991) , the MRF4 C-terminus acts as an activation domain in fusion to MyoD in muscle cells, suggesting that the helix III in the C-terminus of MRF4 is necessary for chromatin remodelling and combines the functions of initiation and activation. This is consistent with the fact that MyoD and MRF4 are some overlapping functions in the muscle differentiation pathway (Rawls et al., 1998; Figure 5c, d ) and supports a model in which a threshold level of expression of the different myogenic b-HLH factors is required to trigger the differentiation program (Rawls et al., 1998) .
The genetic hierarchies controlling skeletal myogenesis have demonstrated that the four MRFs are differently expressed during embryogenesis. MRF4 is expressed transiently in the murine myotome between MRF4 C-terminus induces muscle differentiation in RD cells V Sirri et al embryonic day 9 (E9) and day 11.5 (E 11.5) and then initiates again around E17 and is the major MRF in adult skeletal muscle (Buckingham, 1994) . The double mutation of MyoD and MRF4 resulted in a severe skeletal muscle deficiency, despite normal expression of myogenin indicating that either MyoD or MRF4 was necessary for myogenin to mediate normal muscle differentiation (Rawls et al., 1998) . The coupling of cell cycle arrest and the process of skeletal muscle differentiation induced by MRF4 in RD cells implicate that these cells contain specific cofactor(s) required for MRF4 activity and may represent a target for the isolation of such a cofactor. MRF4 exhibits some unique functions that could contribute to the rescue of the myogenic program in RMS.
Materials and methods
Plasmids
Expression vectors encoding-HA-MRFs were obtained by PCR using full-length MyoD, myogenin and MRF4 plasmids and cloned in pCMV-3HA (Reynaud et al., 1999) . For chimeric protein MyoDD221-318/MRF4 182-242 (MyoD/ MRF4), we created a SmaI site at position aa 821 in MyoD (MyoD/SmaI) by mutagenesis. The C-terminus MyoD (SmaI/ XbaI) was deleted and replaced by the FspI-XbaI insert of MRF4 covering aa 182-242. To generate chimeric protein MRF4 D181-242-MyoD 221-318 (MRF4/MyoD), the Nterminus MyoD (aa 1-220) was replaced by the N-terminus MRF4 (insert EcoRI-FspI covering aa 1-181). The expression vectors encoding MKK6wt, MKK6DD (constitutively activated form) and MKK6AA (inactive form) were a gift of A Nebreda. For Gal4 fusion experiments, we first created an expression vector pCMV-Gal4-HA by inserting in frame the HindIII-ClaI filled in fragment of the Gal4 DNA binding domain at the EcoRV site of pCMV-3HA. Gal4 DBD fusion proteins were generated by PCR amplifying cDNA encoding MRF4 and ligating in frame the PCR products into pCMVGal4-HA. The reporter plasmid 5XGal4-E1b-Luc was constructed by replacing the CAT reporter gene by the Luc reporter gene in the pG5E1bCAT construct. Expression vectors encoding CKI and MCK-Luc have been previously described (Reynaud et al., 1999) . All constructions were verified by sequencing with an automatic laser fluorescence sequencer ABI.
Cell culture, transfections and Luciferase activity C2C12, L6 and 10T1/2 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20, 10 and 15% fetal calf serum, respectively (GM), or 2% fetal calf serum (DM). Human U2OS-derived UTA6 cells were cultured in DMEM supplemented with either 10% fetal calf serum (GM) or 2% fetal calf serum (DM). Human RMS cell lines RD, Rh30 and RhJT were maintained in DMEM supplemented with either 20% fetal calf serum (GM) or 2% fetal calf serum (DM). C2C12, UTA6 and RD cells were transfected by the calcium phosphate; 10T1/2 and L6 cells were transfected by the polyethylenimine (PEI). Transfections were performed using Fugene (Roche Molecular Biochemicals) for Rh30 and RhJT cells. Cells were plated in six-well or 12-well plates and transfected 24 h later with a total of 10 or 4 mg, respectively, of various combinations of plasmids as indicated in the legends of the figures. The total amount of DNA used for each plate was normalized with the respective empty expression vehicle. pEGFP-C1 plasmid (100 ng) (Invitrogen) was included in transfections as internal control for transfection efficiency. Luciferase activity was determined in triplicate on aliquots of cell extracts normalized to protein content with a luminometer (Lumat LB 9507-DLA, Berthold).
Generation of tetracycline-inducible stably MRF4-expressed RD cells
To generate RD-T-Rex clone, we used the T-Rex System (Invitrogen), which is a tetracycline-regulated mammalian expression. An inducible clone was then transfected with pcDNA4/T0-MRF4 and selected with zeocin. Selected clones were picked and subcultured for analysis of MRF4 induction by immunofluorescence after 48 h with and without tetracycline (RD-TRM11 clone).
Flow-cytometry analysis
For flow-cytometry analysis, cells were cotransfected with GFP expression plasmid and harvested, washed with 10 mm EDTA-phosphate-buffered saline (PBS) and fixed with 70% ethanol, 30 min at À201C. DNA was stained with propidium iodide (10 mg/ml) in PBS containing 20 mm EDTA, 0.5% Tween 20 and 125 mg/ml of ribonuclease A, 1 h at 41C. The DNA content of 5000-10 000 cells expressing high levels of GFP was analysed by flow cytometry.
Immunoblot analysis
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Gel loading was normalized to protein concentration. The nitrocellulose membranes were immunoblotted with anti-MyoD (C-20, Santa Cruz) diluted 1 : 250, anti-myogenin (F5D, Pharmingen) diluted 1 : 500, anti-MRF4 (C-19, Santa Cruz) diluted 1 : 1000, anti-p21 (F5, Santa Cruz) diluted 1 : 100, anti-Troponin T (Sigma) diluted 1 : 300, antiMyc (9E10, Santa Cruz) diluted 1 : 1000, anti-Myosin light chain (MLC1, Sigma) diluted 1 : 500, anti-HA (12CA5, Roche) diluted 1 : 1000.
Immunofluorescence
For immunofluorescence, cells were washed in PBS and fixed with 2% paraformaldehyde in 1 Â PBS at room temperature for 20 min. After fixation, cells were permeabilized by incubation with 0.5% Triton X-100 in PBS for 5 min, washed in PBS, and incubated with anti-MRF4 for 1 h. Primary antibody was detected by fluorochrome-conjugated secondary antibody. DNA was stained by DAPI.
